Leave a Comment

Please enter your name.
Please enter a comment.

Trending
Oly Ilunga - March 2019
Debate over whether to test a second Ebola vaccine…
Debate over whether to test a second Ebola vaccine turns acrimonious
Alzheimer's Blood Test
Scientists close in on blood test for Alzheimer’s
Scientists close in on blood test for Alzheimer’s
Heroin and Fentanyl doses
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Recommended
Pharmalittle: Pharma keeps winning in Washington; J&J faces test…
Pharmalittle: Pharma keeps winning in Washington; J&J faces test as Oklahoma opioid trial wraps up
Acupuncture back pain
Medicare proposal would cover acupuncture to treat lower back…
Medicare proposal would cover acupuncture to treat lower back pain for patients in studies
Vertex
Weeks after Kymera signed $70m deal with Vertex, the…
Weeks after Kymera signed $70m deal with Vertex, the biotech’s CEO is out

Recommended Stories

Vertex
Biotech

Weeks after Kymera signed $70m deal with Vertex, the biotech’s CEO is out

By Jonathan Saltzman — Boston Globe

unplug
Politics

After Trump pulled the plug on rebates, his options to reduce drug prices narrow. And he may need Congress

By Andrew Joseph and Damian Garde

Biotech

Mass. Gov. Charlie Baker’s plan to curb drug prices strains his relationship with biotechs

By Priyanka Dayal McCluskey — Boston Globe

Pharmalot

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

By Ed Silverman

Parker book
In the Lab

The Parker Institute looks to grow, leveraging outside donors and equity stakes

By Rebecca Robbins

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy